In a surprising shift of medical demand, the US Growth Hormone Deficiency Market is experiencing a strong upswing, fueled by both clinical advancements and an increasing awareness of growth disorders. This surge is not just about pediatric patients anymore — adults, too, are driving demand in what’s becoming a billion-dollar opportunity for biotech and pharma players. Why...